Jaguar Health (NASDAQ: JAGX) stock plunged over 5% in the pre-market trading Tuesday after the company reported a year-over-year decline in Q4 EPS and revenue below expectations.
Jaguar Health (NASDAQ: JAGX) reported earnings per share (EPS) of 42 cents for the fourth quarter, down from 57 cents year-over-year.
The company reported quarterly revenue of $2.30 million, missing analysts’ estimates of $2.61 million. The figure represents an 18% decrease compared to net revenues of $2.8 million in the previous quarter (Q3 2023) and approximately a 30% decrease compared to net revenue of $3.3 million in the same quarter of the preceding year (Q4 2022).
In addition to the quarterly results, Jaguar Health revealed its net revenue for the year ended December 31, 2023, which stood at around $9.8 million. This figure represents a decline of 18% compared to the net revenue of approximately $12.0 million reported for the year ended December 31, 2022.
Jaguar Health (NASDAQ: JAGX) Stock Reaction
JAGX stock plummeted 14.35% to close at $0.08 on Monday. The traders had exchanged hands with 73,082,520 (73.08 million) shares compared to the average daily trading volume of 39.45 million. The stock has a market capitalization of $16.08 million.
Edward Cooke is a financial analyst, freelance writer, and editor. He has six years of experience in financial journalism. He has an in-depth understanding of equities markets, tracking major indices and providing real-time analysis on stock price movements, corporate earnings, and market sentiment.
